华法林药代动力学过程影响因素研究进展

中国临床药理学与治疗学 ›› 2017, Vol. 22 ›› Issue (11): 1292-1298.

华法林药代动力学过程影响因素研究进展

李海刚¹，范蓉²，马宁²，唐靖³，廖鸿纯⁴，郑霞辉⁵

¹长沙医学院药理教研室， ²药学院， ³药剂教研室，⁴病理教研室，长沙 410219，湖南; ⁵湖南九典制药股份有限公司，长沙 410329，湖南

收稿日期:2017-08-30 修回日期:2017-10-22 出版日期:2017-11-26 发布日期:2017-12-11
通讯作者: 廖鸿纯，男，本科，讲师，研究方向为病理生理学。 E-mail:609879275@qq.com
作者简介:李海刚，男，博士，讲师，研究方向为中西医结合临床基础、神经药理学。 E-mail:138101039@csu.edu.cn
基金资助:
国家自然科学基金青年项目（81603061）；2014年湖南省校企合作人才培养示范基地项目（湘教通［2014］272号）；新型药物制剂研发湖南省重点实验室培育基地（2016TP1029）

Research progress on pharmacokinetics factors of warfarin

LI Haigang ¹, FAN Rong², MA Ning², TANG Jing³, LIAO Hongchun ⁴, ZHENG Xiahui ⁵

¹Department of Pharmacology, Changsha Medical University, ² Department of Pharmacy, Changsha Medical University, ³Department of Pharmaceutics, Changsha Medical University, ⁴ Department of Pathology, Changsha Medical University, Changsha 410219, Hunan, China; ⁵ Hunan Jiudian Pharmaceutical Co., Ltd,Changsha 410319, Hunan, China

Received:2017-08-30 Revised:2017-10-22 Online:2017-11-26 Published:2017-12-11

摘要/Abstract

摘要：

华法林作为临床上应用最广泛的口服抗凝药，因其较窄的治疗窗，绝大部分关于华法林的文献资料均聚焦于其安全性和临床剂量的设计。目前各种华法林临床剂量调整的预测公式往往只能解释华法林40%～60%的剂量个体化差异。本文对华法林体内药代动力学过程的诸多影响因素及可能的药物相互作用进行了文献分析，以期为促进华法林的临床合理应用提供药代动力学方面的依据。

关键词: 华法林, 药代动力学, 药物相互作用

Abstract:

Warfarin is the most frequently used oral anticoagulants, but most literatures of it focused on the safety and clinical dosages design due to its narrow therapeutic window. The various prediction formulae of clinical dose-adjustment of warfarin can only interpreter 40%-60% individualized difference of warfarin. This article reviews literatures about the factors influencing pharmacokinetics of warfarin and its potential drug interactions so as to provide referential evidences for the rational application of warfarin into clinic.

Key words: warfarin, pharmacokinetics, drug interaction

中图分类号:

R969.1

李海刚，范蓉，马宁，唐靖，廖鸿纯，郑霞辉. 华法林药代动力学过程影响因素研究进展[J]. 中国临床药理学与治疗学, 2017, 22(11): 1292-1298.

LI Haigang, FAN Rong, MA Ning, TANG Jing, LIAO Hongchun, ZHENG Xiahui. Research progress on pharmacokinetics factors of warfarin[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(11): 1292-1298.

参考文献

［1］Mega JL, Simon T. Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments［J］. Lancet, 2015, 386(9990): 281-291.
［2］Johnson JA, Gong L, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing［J］. Clin Pharmacol Ther, 2011, 90(4): 625-629.
［3］Wadelius M, Chen LY, Lindh JD, et al. The largest prospective warfarin-treated cohort supports genetic forecasting［J］. Blood, 2009, 113(4): 784-792.
［4］Verhoef TI, Redekop WK, Daly AK, et al. Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon［J］. Br J Clin Pharmacol, 2014, 77(4): 626-641.
［5］Anderson JL, Horne BD, Stevens SM, et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation［J］. Circulation, 2007, 116(22): 2563-2570.
［6］Yin T, Miyata T. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives［J］. Thromb Res,2007, 120(1): 1-10.
［7］刘会臣. 手性药物的药代动力学立体选择性及其影响因素研究进展［J］. 中国临床药理学杂志, 2003,8(5): 380-383.
［8］李琳，张炜，沈陈林，等. 阿司匹林与华法林在体肠吸收的相互作用研究［J］. 中国临床药理学与治疗学, 2015,20(5): 486-492.
［9］Shen C, Huang X, Li J, et al. Pharmacokinetic and pharmacodynamic interactions of aspirin with warfarin in beagle dogs［J］. Xenobiotica, 2016, 46(6): 530-541.
［10］黄晓晖，王夏芹，唐海沁，等. 华法林和阿司匹林联用在大鼠体内的药代动力学研究(英文)［J］. 中国临床药理学与治疗学, 2012,17(2): 189-195.
［11］Niopas I, Toon S, Aarons L, et al. The effect of cimetidine on the steady-state pharmacokinetics and pharmacodynamics of warfarin in humans［J］. Eur J Clin Pharmacol, 1999, 55(5): 399-404.
［12］Impellizzeri P, Centonze A, Antonuccio P, et al. Utility of a scoring system in the diagnosis of acute appendicitis in pediatric age. A retrospective study［J］. Minerva Chir, 2002, 57(3): 341-346.
［13］Leschziner GD, Andrew T, Pirmohamed M, et al. ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research［J］. Pharmacogenomics J, 2007, 7(3): 154-179.
［14］De Oliveira AV, De Souza FA, Ribeiro DD, et al. Association of the C3435T polymorphism of the MDR1 gene and therapeutic doses of warfarin in thrombophilic patients［J］. J Thromb Haemost, 2011, 9(10): 2120-2122.
［15］Wadelius M, Sorlin K, Wallerman O, et al. Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors［J］. Pharmacogenomics J, 2004, 4(1): 40-48.
［16］Chai GH, Hu FQ, Sun J, et al. Transport pathways of solid lipid nanoparticles across Madin-Darby canine kidney epithelial cell monolayer［J］. Mol Pharm, 2014, 11(10): 3716-3726.
［17］Wadhera RK, Russell CE, Piazza G. Cardiology patient page. Warfarin versus novel oral anticoagulants: how to choose［J］? Circulation, 2014, 130(22): e191-e193.
［18］Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors［J］. Clin Pharmacokinet, 2002, 41(5): 343-370.
［19］Ermer JC, Hicks DR, Wheeler SC, et al. Concomitant etodolac affects neither the unbound clearance nor the pharmacologic effect of warfarin［J］. Clin Pharmacol Ther, 1994, 55(3): 305-316.
［20］Toon S, Trager WF. Pharmacokinetic implications of stereoselective changes in plasma-protein binding: warfarin/sulfinpyrazone［J］. J Pharm Sci, 1984, 73(11): 1671-1673.
［21］Lewis RJ, Trager WF. Warfarin metabolism in man: identification of metabolites in urine［J］. J Clin Invest, 1970, 49(5): 907-913.
［22］Lewis RJ, Trager WF, Robinson AJ, et al. Warfarin metabolites: the anticoagulant activity and pharmacology of warfarin alcohols［J］. J Lab Clin Med, 1973, 81(6): 925-931.
［23］Gebauer M. Synthesis and structure-activity relationships of novel warfarin derivatives［J］. Bioorg Med Chem, 2007, 15(6): 2414-2420.
［24］Jones DR, Miller GP. Assays and applications in warfarin metabolism: what we know, how we know it and what we need to know［J］. Expert Opin Drug Metab Toxicol, 2011, 7(7): 857-874.
［25］Takahashi H, Kashima T, Nomoto S, et al. Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes［J］. Pharmacogenetics, 1998, 8(5): 365-373.
［26］Jones DR, Kim SY, Boysen G, et al. Contribution of three CYP3A isoforms to metabolism of R- and S-warfarin［J］. Drug Metab Lett, 2010, 4(4): 213-219.
［27］Kaminsky LS, de Morais SM, Faletto MB, et al. Correlation of human cytochrome P4502C substrate specificities with primary structure: warfarin as a probe［J］. Mol Pharmacol,1993, 43(2): 234-239.
［28］Rettie AE, Korzekwa KR, Kunze KL, et al. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions［J］. Chem Res Toxicol, 1992, 5(1): 54-59.
［29］Zhang Z, Fasco MJ, Huang Z, et al. Human cytochromes P4501A1 and P4501A2: R-warfarin metabolism as a probe［J］. Drug Metab Dispos, 1995, 23(12): 1339-1346.
［30］Miller GP. Warfarin therapy: how the less interesting half just got interesting［J］. J Thromb Haemost, 2010, 8(12): 2705-2707.
［31］Ritter JK. Roles of glucuronidation and UDP-glucuronosyltransferases in xenobiotic bioactivation reactions［J］. Chem Biol Interact, 2000, 129(1/2): 171-193.
［32］Zielinska A, Lichti CF, Bratton S, et al. Glucuronidation of monohydroxylated warfarin metabolites by human liver microsomes and human recombinant UDP-glucuronosyltransferases［J］. J Pharmacol Exp Ther, 2008, 324(1): 139-148.
［33］Miller GP, Jones DR, Sullivan SZ, et al. Assessing cytochrome P450 and UDP-glucuronosyltransferase contributions to warfarin metabolism in humans［J］. Chem Res Toxicol,2009, 22(7): 1239-1245.
［34］Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions［J］. Arch Intern Med, 2005, 165(10): 1095-1106.
［35］Andrus MR. Oral anticoagulant drug interactions with statins: case report of fluvastatin and review of the literature［J］. Pharmacotherapy, 2004, 24(2): 285-290.
［36］Nutescu E, Chuatrisorn I, Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update［J］. J Thromb Thrombolysis, 2011, 31(3): 326-343.
［37］Dionisio D, Mininni S, Bartolozzi D, et al. Need for increased dose of warfarin in HIV patients taking nevirapine［J］. AIDS, 2001, 15(2): 277-278.
［38］陈刚，杨劲，张广钦. 华法林与胺碘酮相互作用研究进展［J］. 中国临床药理学与治疗学, 2017,22(2): 215-221.
［39］Lim MK, Sadarangani P, Chan HL, et al. Complementary and alternative medicine use in multiracial Singapore［J］. Complement Ther Med, 2005, 13(1): 16-24.
［40］Cuzzolin L, Francini-Pesenti F, Zaffani S, et al. Knowledges about herbal products among subjects on warfarin therapy and patient-physician relationship: a pilot study［J］. Pharmacoepidemiol Drug Saf, 2007, 16(9): 1014-1017.
［41］Ramsay NA, Kenny MW, Davies G, et al. Complimentary and alternative medicine use among patients starting warfarin［J］. Br J Haematol, 2005, 130(5): 777-780.
［42］Wong RS, Cheng G, Chan TY. Use of herbal medicines by patients receiving warfarin［J］. Drug Saf, 2003, 26(8): 585-588.
［43］Wang Z, Roberts JM, Grant PG, et al. The effect of a medicinal Chinese herb on platelet function［J］. Thromb Haemost, 1982, 48(3): 301-306.
［44］Wu WW, Yeung JH. Inhibition of warfarin hydroxylation by major tanshinones of Danshen (Salvia miltiorrhiza) in the rat in vitro and in vivo［J］. Phytomedicine, 2010, 17(3/4): 219-226.
［45］Zou L, Harkey MR, Henderson GL. Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity［J］. Life Sci, 2002, 71(13): 1579-1589.
［46］Liu Y, Zhang JW, Li W, et al. Ginsenoside metabolites, rather than naturally occurring ginsenosides, lead to inhibition of human cytochrome P450 enzymes［J］. Toxicol Sci, 2006, 91(2): 356-364.
［47］Gurley BJ, Gardner SF, Hubbard MA, et al. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans［J］. Clin Pharmacol Ther, 2002, 72(3): 276-287.
［48］Kent UM, Aviram M, Rosenblat M, et al. The licorice root derived isoflavan glabridin inhibits the activities of human cytochrome P450S 3A4, 2B6, and 2C9［J］. Drug Metab Dispos, 2002, 30(6): 709-715.
［49］Coderre K, Faria C, Dyer E. Probable warfarin interaction with menthol cough drops［J］. Pharmacotherapy, 2010, 30(1): 110.
［50］Dresser GK, Wacher V, Wong S, et al. Evaluation of peppermint oil and ascorbyl palmitate as inhibitors of cytochrome P4503A4 activity in vitro and in vivo［J］. Clin Pharmacol Ther, 2002, 72(3): 247-255.
［51］Mohammed AM, Jiang X, Williams KM, et al. Pharmacodynamic interaction of warfarin with cranberry but not with garlic in healthy subjects［J］. Br J Pharmacol, 2008, 154(8): 1691-1700.
［52］Booth SL, Madabushi HT, Davidson KW, et al. Tea and coffee brews are not dietary sources of vitamin K-1 (phylloquinone)［J］. J Am Diet Assoc, 1995, 95(1): 82-83.
［53］Shord SS, Shah K, Lukose A. Drug-botanical interactions: a review of the laboratory, animal, and human data for 8 common botanicals［J］. Integr Cancer Ther, 2009, 8(3): 208-227.
［54］Toon S, Low LK, Gibaldi M, et al. The warfarin-sulfinpyrazone interaction: stereochemical considerations［J］. Clin Pharmacol Ther, 1986, 39(1): 15-24.
［55］Zhou L, Wang S, Zhang Z, et al. Pharmacokinetic and pharmacodynamic interaction of Danshen-Gegen extract with warfarin and aspirin［J］. J Ethnopharmacol, 2012, 143(2): 648-655.
［56］程娟，李俊，宋珏，等. A771726在大鼠体内肝肠循环的研究［J］. 安徽医科大学学报, 2010,56 (3): 338-341.
［57］Li H, Wang Y, Fan R, et al. The effects of ferulic acid on the pharmacokinetics of warfarin in rats after biliary drainage［J］. Drug Des Devel Ther, 2016, 10: 2173-2180.
［58］Li H, Zhang C, Fan R, et al. The effects of Chuanxiong on the pharmacokinetics of warfarin in rats after biliary drainage［J］. J Ethnopharmacol, 2016, 193: 117-124.
［59］Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action［J］. Arch Intern Med, 2007, 167(13): 1414-1419.
［60］Beyth RJ, Milligan PE, Gage BF. Risk factors for bleeding in patients taking coumarins［J］. Curr Hematol Rep, 2002, 1(1): 41-49.
［61］Fang MC, Go AS, Chang Y, et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages［J］. Am J Med, 2007, 120(8): 700-705.
［62］Liu J, Jiang HH, Wu DK, et al. Effect of gene polymorphims on the warfarin treatment at initial stage［J］. Pharmacogenomics J, 2017, 17(1):47-52.
［63］Hirsh J, Fuster V, Ansell J, et al. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy［J］. J Am Coll Cardiol, 2003, 41(9): 1633-1652.
［64］Wittkowsky AK. Factors associated with INR elevation and bleeding complications during Warfarin therapy［J］. Arch Intern Med, 2005, 165(6): 703.
［65］Marcatto LR, Sacilotto L, Darrieux FC, et al. Age is associated with time in therapeutic range for warfarin therapy in patients with atrial fibrillation［J］. Oncotarget, 2016, 7(34):54194-54199.
［66］Moreau C, Bajolle F, Siguret V, et al. Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement［J］. Blood, 2012, 119(3): 861-867.
［67］Self TH, Wallace JL, Sakaan S, et al. Effect of body weight on dose of vitamin K antagonists［J］. South Med J, 2015, 108(10): 637-643.
［68］Klein TE, Altman RB, Eriksson N, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data［J］. N Engl J Med, 2009, 360(8): 753-764.
［69］Pirmohamed M, Kamali F, Daly AK, et al. Oral anticoagulation: a critique of recent advances and controversies［J］. Trends Pharmacol Sci, 2015, 36(3): 153-163.
［70］Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose［J］. N Engl J Med, 2005, 352(22): 2285-2293.
［71］Rettie AE, Wienkers LC, Gonzalez FJ, et al. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9［J］. Pharmacogenetics, 1994, 4(1): 39-42.
［72］Zhao Z, Moghadasian MH. Chemistry, natural sources, dietary intake and pharmacokinetic properties of ferulic acid: A review［J］. Food Chem, 2008, 109(4): 691-702.
［73］Soucek P, Gut I. Cytochromes P-450 in rats: structures, functions, properties and relevant human forms［J］. Xenobiotica, 1992, 22(1): 83-103.
［74］Tadros R, Shakib S. Warfarin--indications, risks and drug interactions［J］. Aust Fam Physician, 2010, 39(7): 476-479.

[1]	何雪茹, 李颖, 马银玲, 付裕豪, 荀雪姣, 董占军. 索拉非尼和达格列净在大鼠体中药代动力学相互作用研究[J]. 中国临床药理学与治疗学, 2023, 28(5): 498-507.
[2]	刘秀梅, 郭倩倩, 方圆, 陈楠, 齐琦. 经颈静脉肝内门体分流术后患者抗栓治疗的药学监护实践[J]. 中国临床药理学与治疗学, 2023, 28(5): 556-560.
[3]	李梦雪, 何杰, 余霞霞, 胡琳璘, 邵华. 利妥昔单抗群体药代动力学研究进展[J]. 中国临床药理学与治疗学, 2023, 28(4): 468-474.
[4]	周佳婷, 张玄, 谢子兰, 李智. 肠道菌群与左旋甲状腺素：相互影响与临床意义[J]. 中国临床药理学与治疗学, 2023, 28(11): 1307-1314.
[5]	吴莉莉, 梁至, 黄思咏, 王妍. 肾功能亢进对感染性心内膜炎患者万古霉素药动学的影响及有效性与安全性研究[J]. 中国临床药理学与治疗学, 2023, 28(10): 1139-1145.
[6]	徐涛, 朱素燕, 邱相君, 徐萍. 肾功能不全患者人群中替考拉宁群体药代动力学模型的建立与验证[J]. 中国临床药理学与治疗学, 2022, 27(9): 977-983.
[7]	马申, 刘玉硕, 唐辉, 陈文斌, 高聆. 改善非酒精性脂肪性肝病药物的药代动力学及其临床意义[J]. 中国临床药理学与治疗学, 2022, 27(8): 908-918.
[8]	何雪茹, 付裕豪, 荀雪姣, 崔艳军, 董占军. 尿苷二磷酸葡醛酸转移酶介导的酪氨酸激酶抑制剂药物相互作用研究进展[J]. 中国临床药理学与治疗学, 2022, 27(8): 936-945.
[9]	戴静怡, 王晶晶, 张菁, 郁继诚, 李南洋, 黄志伟. 吸入性甲氧氟烷的临床应用及研究进展[J]. 中国临床药理学与治疗学, 2022, 27(7): 808-813.
[10]	武元竹, 刘俊, 杨魁, 彭静, 栾家杰, 韦俊, 张大发, 宋帅, 袁小龙, 王中方, 张年宝, 解丹, 姜鹏, 范洁. 安徽地区汉族人群CYP2C9*3和VKORC1-1639G>A基因多态性分布及对华法林稳定剂量的影响[J]. 中国临床药理学与治疗学, 2022, 27(6): 652-659.
[11]	潘淑, 吴义金, 张洒洒, 王启海, 罗婷婷, 殷勤. 基于OAT3介导的MTX治疗佐剂诱导性关节炎大鼠的药动学研究[J]. 中国临床药理学与治疗学, 2022, 27(5): 516-525.
[12]	连金芳, 刘亦伟, 林翠鸿, 黄品芳, 林荣芳. 华法林PPK/PD模型与多元回归法剂量模型的预测准确度比较[J]. 中国临床药理学与治疗学, 2022, 27(3): 267-273.
[13]	吴娟, 王志强, 周仁鹏, 杨晶晶, 秦慧玲, 张茜, 鲁超, 胡伟. 甲苯磺酸索拉非尼片在中国健康受试者的生物等效性研究[J]. 中国临床药理学与治疗学, 2022, 27(3): 281-286.
[14]	张进华, 刘茂柏, 蔡铭智, 郑英丽, 劳海燕, 向倩, 都丽萍, 朱珠, 董婧, 左笑丛, 李新刚, 尚德为, 陈冰, 叶岩荣, 王玉珠, 高建军, 张健, 陈万生, 谢海棠, 焦正. 模型引导的华法林精准用药：中国专家共识（2022版）[J]. 中国临床药理学与治疗学, 2022, 27(11): 1201-1212.
[15]	史革鑫, 崇锐, 贺坤, 吴海棠, 周宇, 顿中军, 温清, 张继国, 张荣. 吗替麦考酚酯胶囊在中国健康男性受试者空腹及餐后状态下的完全重复交叉设计的生物等效性研究[J]. 中国临床药理学与治疗学, 2022, 27(11): 1255-1263.